From October 2014 to December 2019, in the uncommon EGFR mutation-positive NSCLC group, the median PFS was 15.1 months (95% CI: 12.5–17.7) for afatinib and 7.7 months (95% CI: 1.3–14.1) for gefitinib or erlotinib (Table 2 and Figure 1A) (p = 0.165). Here, EGFR is linked to non-small cell lung carcinoma.